Novel pharmacologic approaches to the management of sepsis: Targeting the host inflammatory response

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 3, Issue 2, 2009, Pages 96-112

  Wheeler, Derek S ^a,b   Zingarelli, Basilia ^a,b   Wheeler, William J ^c   Wong, Hector R ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c Isotopic Solutions LLC   (United States)

Author keywords

Adult; Critical illness; Danger signals; Gene polymorphisms; Genomics; Heat shock proteins; Inflammation; LPS; NF B; Pediatric; Sepsis; Septic shock; Toll like receptors

Indexed keywords

CD14 ANTIGEN; CHAPERONIN; ERITORAN; FLUDROCORTISONE; HEAT SHOCK PROTEIN 90; HIGH MOBILITY GROUP B1 PROTEIN; HYDROCORTISONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPID BINDING PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN PROTEIN; PATTERN RECOGNITION RECEPTOR; PLACEBO; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; ACUTE PHASE PROTEIN; ANTIMICROBIAL CATIONIC PEPTIDE; CARRIER PROTEIN; CORTICOSTEROID; CYTOKINE; HIGH DENSITY LIPOPROTEIN; IMMUNOLOGIC FACTOR; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; IMMUNOLOGY; METABOLISM;

ACUTE-PHASE PROTEINS; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD14; ANTIMICROBIAL CATIONIC PEPTIDES; CARRIER PROTEINS; CYTOKINES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; LIPOPROTEINS, HDL; MEMBRANE GLYCOPROTEINS; NF-KAPPA B; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 68949192654     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221309788489779     Document Type: Review

References (235)

1. American College of Chest Physicians and Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-874.
2. Marshall JC. SIRS and MODS: What is their relevance to the science and practice of intensive care? Shock 2000; 14: 586-589.
3. Baue AE. A debate on the subject "Are SIRS and MODS important entities in the clinical evaluation of patients?" The con position. Shock 2000; 14: 590-593.
4. Vincent JL. Dear Sirs, I'm sorry to say that I don't like you. Crit Care Med 1997; 25: 372-374.
5. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31: 1250-1256.
6. Denoix PX. Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg 1946; 1: 70-75.
7. Opal SM. Concept of PIRO as a new conceptual framework to understand sepsis. Pediatr Crit Care Med 2005; 6: S55-S60.
8. Heron M. Deaths: Leading causes for 2004. Natl Vital Stat Rep 2007; 56: 1-95.
9. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348: 1546-1554.
10. Finfer S, Bellomo R, Lipman J, French C, Dobb G, Myburgh J. Adult population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-596.
11. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome and associated costs of care. Crit Care Med 2001; 29: 1303-1310.
12. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: A trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244-1250.
13. Ponce de Leon-Rosales SP, Molinar-Ramos F, Dominquez-Cherit G, Rangel-Frausto MS, Vazquez-Ramos VG. Prevalence of infections in intensive care units in Mexico: A multicenter study. Crit Care Med 2000; 28: 1316-1321.
14. Alberti C, Brun-Buisson C, Burchardi H, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-121.
15. Padkin A, Goldfrad C, Brady A, Young D, Black N, Rowan K. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31: 2332-2338.
16. Silva E, Pedro Mde A, Sogayar AC, et al. Brazilian Sepsis Epidemiological Study (BASES study). Crit Care 2004; 8: R251-R260.
17. Cheng B, Xie G, Yao S, et al. Epidemiology of severe sepsis in critically ill surgical patients in ten university hospitals in China. Crit Care Med 2007; 35: 2538-2546.
18. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: Results of the SOAP study. Crit Care Med 2006; 34: 344-353.
19. Murch O, Collin M, Hinds CJ, Thiemermann C. Lipoproteins in inflammation and sepsis. I. Basic science. Intensive Care Med 2007; 33: 13-24.
20. Watson RS, Carcillo JA, Linde-Zwirble WT, Clermont G, Lidicker J, Angus DC. The epidemiology of severe sepsis in children in the United States. Am J Respir Crit Care Med 2003; 167: 695-701.
21. Rice TW. Treatment of severe sepsis: Where next? Current and future treatment approaches after the introduction of drotrecogin alfa. Vasc Health Risk Manag 2006; 2: 3-18.
22. Trzeciak S, Cinel I, Dellinger RP, et al. Resuscitating the microcirculation in sepsis: The central role of nitric oxide, emerging concepts for novel therapies and challenges for clinical trials. Acad Emerg Med 2008; 15: 399-413.
23. Marshall JC. Sepsis: Rethinking the approach to clinical research. J Leukoc Biol 2008; 83: 471-482.
24. Derkx B, Wittes J, McCloskey R. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 1999; 28(4): 770-777.
25. Giroir BP, Quint PA, Barton P, et al. Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/ permeability-increasing protein in children with severe meningococcal sepsis. Lancet 1997; 350(9089): 1439-1443.
26. Levin M, Quint PA, Goldstein B, et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: A randomized trial. Lancet 2000; 356: 961-967.
27. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-1377.
28. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344(10): 699-709.
29. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med 2004; 32: 2173-2182.
30. Marik PE, Varon J. Goal-directed therapy for severe sepsis. N Engl J Med 2002; 346: 1025-1026.
31. Abroug F, Besbes L, Nouira S. Goal-directed therapy for severe sepsis. N Engl J Med 2002; 346: 1025-1026.
32. Sarkar S, Kupfer Y, Tessler S. Goal-directed therapy for severe sepsis. N Engl J Med 2002; 346: 1026.
33. Donnino MW, Talmor D. A central venous pressure goal of 8-12 mm Hg for all patients in septic shock. Crit Care Med 2007; 35: 1441-1442.
34. Burton TM. New therapy for sepsis infections raises hope but many questions. Wall St J 2008 [cited 2008 August 14]; Available from: http://online.wsj.com/article/SB12186719036438865.html?mod= dist_smartbrief#articleTabs%3Darticle
35. Han YY, Carcillo JA, Dragotta MA, et al. Early reversal of pediatric-neonatal septic shock by community physicians is associated with improved outcome. Pediatrics 2003; 112: 793-799.
36. de Oliveira CF, de Oliveira DS, Gottschald AF, et al. ACCM/PALS haemodynamic support guidelines for paediatric septic shock: An outcomes comparison with and without monitoring of central venous oxygen saturation. Intensive Care Med 2008; 34: 1065-1075.
37. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: A multicentre phase III randomised controlled trial. Lancet 2007; 369: 836-843.
38. Finfer S, Ranieri VM, Thompson BT, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008; 34: 1935-1947.
39. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-871.
40. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358: 111-124.
41. Laupland KB, Kirkpatrick AW, Delaney A. Polyclonal intravenous immuneglobulin for the treatment of severe sepsis and septic shock in critically ill adults: A systematic review and meta-analysis. Crit Care Med 2007; 35: 2686-2692.
42. Levi M, de Jonge E, van der Poll T. Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation. Crit Care Med 2001; 29: S90-S94.
43. Feistritzer C, Wiedermann CJ. Effects of anticoagulant strategies on activation of inflammation and coagulation. Expert Opin Biol Ther 2007; 7: 855-870.
44. Cornet AD, Smit EG, Beishuizen A, Groeneveld AB. The role of heparin and allied compounds in the treatment of sepsis. Thromb Haemost 2007; 98: 579-586.
45. Oberholzer A, Oberholzer C, Minter RM, Moldawer LL. Considering immunomodulatory therapies in the septic patient: Should apoptosis be a potential therapeutic target? Immunol Lett 2001; 75: 221-224.
46. Oberholzer C, Oberholzer A, Clare-Salzler M, Moldawer LL. Apoptosis in sepsis: A new target for therapeutic exploration. FASEB J 2001; 15: 879-892.
47. Ayala A, Wesche-Soldato DE, Perl M, Lomas-Neira JL, Swan R, Chung C-S. Blockade of apoptosis as a rational therapeutic strategy for the treatment of sepsis. Novartis Found Symp 2007; 280: 37-164.
48. Hotchkiss RS, Coopersmith CM, Karl IE. Prevention of lymphocyte apoptosis - a potential treatment of sepsis? Clin Infect Dis 2005; 41: S465-S469.
49. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6: 813-822.
50. Berger MM. Antioxidant micronutrients in major trauma and burns: Evidence and practice. Nutr Clin Pract 2006; 21: 438-449.
51. Berger MM, Chiolero RL. Antioxidant supplementation in sepsis and systemic inflammatory response syndrome. Crit Care Med 2007; 35: S584-S590.
52. Eaton S. The biochemical basis of antioxidant therapy in critical illness. Proc Nutr Soc 2006; 65: 242-249.
53. Heyland DK, Dhaliwal R, Suchner U, Berger MM. Antioxidant nutrients: A systematic review of trace elements and vitamins in the critically ill patient. Intensive Care Med 2005; 31: 327-337.
54. Roth E, Manhart N, Wessner B. Assessing the antioxidant status in critically ill patients. Curr Opin Clin Nutr Metab Care 2004; 7: 161-168.
55. Hauser B, Bracht H, Matejovic M, Radermacher P, Venkatesh B. Nitric oxide synthase inhibition in sepsis? Lessons learned from large-animal studies. Anesth Analg 2005; 101: 488-498.
56. Cauwels A. Nitric oxide in shock. Kidney Int 2007; 72: 557-565.
57. Harbrecht BG. Therapeutic use of nitric oxide scavengers in shock and sepsis. Curr Pharm Des 2006; 12: 3543-3549.
58. Hazelzet J, Driessen GJA, Abboud P, Wheeler DS, Shanley TP, Wong HR. Sepsis. In: Wheeler DS, Wong HR, Shanley TP, Eds. Pediatric Critical Care Medicine: Basic Science and Clinical Evidence. London, UK: Springer-Verlag London Limited 2007; pp. 1421-1444.
59. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-150.
60. Shanley TP, Hallstrom C, Wong HR. Sepsis. In: Fuhrman BP, Zimmerman JJ, Eds. Pediatric Critical Care Medicine. 3rd ed. St. Louis: Mosby 2006; 1474-1493.
61. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348(2): 138-150.
62. Marik PE, Zaloga GP. Hypothermia and cytokines in septic shock. Norasept II Study Investigators. North American study of the safety and efficacy of murine monoclonal antibody to tumor necrosis factor for the treatment of septic shock. Intensive Care Med 2000; 26(6): 716-721.
63. Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet 1998; 351(9107): 929-933.
64. Fisher CJ Jr, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334(26): 1697-1702.
65. Pittet D, Harbarth S, Suter PM, et al. Impact of immunomodulating therapy on morbidity in patients with severe sepsis. Am J Respir Crit Care Med 1999; 160(3): 852-857.
66. Butty VL, Roux-Lombard P, Garbino J, Dayer JM, Ricou B. Antiinflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis. Eur Cytokine Netw 2003; 14(1): 15-19.
67. Reinhart K, Wiegand-Lohnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, doseranging study. Crit Care Med 1996; 24(5): 733-742.
68. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med1994; 121(1): 1-5.
69. The French National Registry of HA-1A (Centoxin) in septic shock. A cohort study of 600 patients. The National Committee for the Evaluation of Centoxin. Arch Intern Med 1994; 154(21): 2484-2491.
70. Kett DH, Quartin AA, Sprung CL, et al. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody. Crit Care Med 1994; 22(8): 1227-1234.
71. van Hout BA, Birnie E, Redekop WK, Lorijn RH, Bossuyt PM, Rutten FF. Cost-effectiveness of HA-1A treatment for patients with sepsis. Prog Clin Biol Res 1994; 388: 435-443.
72. Schulman KA, Glick HA, Rubin H, Eisenberg JM. Cost-effectiveness of HA-1A monoclonal antibody for gram-negative sepsis. Economic assessment of a new therapeutic agent. JAMA 1991; 266(24): 3466-3471.
73. Quintiliani R, Cooper B, Maderazo E, Nightingale C. Comparison of the efficacy, safety and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis. Hosp Formul 1992; 27(1): 49-52.
74. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: Results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23(6): 994-1006.
75. Angus DC, Birmingham MC, Balk RA, et al. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: A randomized controlled trial. E5 Study Investigators. JAMA 2000; 283(13): 1723-1730.
76. Greenman RL, Schein RM, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266(8): 1097-1102.
77. Fisher CJ Jr, Opal SM, Lowry SF, et al. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circ Shock1994; 44(1): 1-8.
78. Lopez A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit Care Med 2004; 32(1): 21-30.
79. Lauterbach R, Pawlik D, Kowalczyk D, Ksycinski W, Helwich E, Zembala M. Effect of the immunomodulating agent, pentoxifylline, in the treatment of sepsis in prematurely delivered infants: A placebo-controlled, double-blind trial. Crit Care Med 1999; 27(4): 807-814.
80. LaRosa SP, Opal SM. Tissue factor pathway inhibitor and antithrombin trial results. Crit Care Clin 2005; 21(3): 433-448.
81. Freeman BD, Zehnbauer BA, Buchman TG. A meta-analysis of controlled trials of anticoagulant therapies in patients with sepsis. Shock 2003; 20(1): 5-9.
82. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104(3): 882-888.
83. Eisele B, Lamy M. Clinical experience with antithrombin III concentrates in critically ill patients with sepsis and multiple organ failure. Semin Thromb Hemost 1998; 24(1): 71-80.
84. Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial. JAMA 2001; 286(15): 1869-1878.
85. Inthorn D, Hoffmann JN, Hartl WH, Muhlbayer D, Jochum M. Antithrombin III supplementation in severe sepsis: Beneficial effects on organ dysfunction. Shock 1997; 8(5): 328-334.
86. Ilias W, List W, Decruyenaere J, et al. Antithrombin III in patients with severe sepsis: A pharmacokinetic study. Intensive Care Med 2000; 26(6): 704-715.
87. Eisele B, Lamy M, Thijs LG, et al. Antithrombin III in patients with severe sepsis. A randomized, placebo- controlled, doubleblind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med 1998; 24(7): 663-672.
88. Abraham E, Reinhart K, Opal S, et al. Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: A randomized, controlled trial. JAMA 2003; 290: 238-247.
89. Abraham E, Reinhart K, Svoboda P, et al. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo- controlled, single-blind, dose escalation study. Crit Care Med 2001; 29(11): 2081-2089.
90. Schuster DP, Metzler M, Opal S, et al. Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis: Phase IIb, multicenter, randomized, placebo-controlled, clinical trial. Crit Care Med 2003; 31(6): 1612-1619.
91. Opal S, Laterre PF, Abraham E, et al. Recombinant human plateletactivating factor acetylhydrolase for treatment of severe sepsis: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med 2004; 32(2): 332-341.
92. Zeiher BG, Steingrub J, Laterre PF, Dmitrienko A, Fukiishi Y, Abraham E. LY315920NA/S-5920, a selective inhibitor of group IIA secretory phospholipase A2, fails to improve clinical outcome for patients with severe sepsis. Crit Care Med 2005; 33(8): 1741-1748.
93. Jenkins JK, Carey PD, Byrne K, Sugerman HJ, Fowler AA. Sepsis-induced lung injury and the effects of ibuprofen pretreatment. Analysis of early alveolar events via repetitive bronchoalveolar lavage. Am Rev Respir Dis 1991; 143(1): 155-161.
94. Haupt MT, Jastremski MS, Clemmer TP, Metz CA, Goris GB. Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. The Ibuprofen Study Group. Crit Care Med 1991; 19(11): 1339-1347.
95. Marshall JC, Vincent JL, Fink MP, et al. Measures, markers and mediators: Toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 2003; 31: 1560-1567.
96. Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 2005; 24: 107-119.
97. Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev 2007; 18: 335-343.
98. McKenna, J.M., Papa, P.W., Sakata, S. T., Erdman, P. E., Packard, G.K.: US20080004271(2008).
99. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002; 34: 1084-1093.
100. Fannin RD, Auman JT, Bruno ME, et al. Differential gene expression profiling in whole blood during acute systemic inflammation in lipopolysaccharide-treated rats. Physiol Genomics 2005; 21: 92-104.
101. Brownstein BH, Logvinenko T, Lederer JA, et al. Commonality and differences in leukocyte gene expression patterns among three models of inflammation and injury. Physiol Genomics 2006; 24: 298-309.
102. Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature 2005; 437(7061): 1032-1037.
103. Wong HR, Shanley TP, Sakthivel B, et al. Genome-level expression profiles in pediatric septic shock indicate a role for altered zinc homeostasis in poor outcome. Physiol Genomics 2007; 30(2): 146-155.
104. Shanley TP, Cvijanovich N, Lin R, et al. Genome-level longitudinal expression of signaling pathways and gene networks in pediatric septic shock. Mol Med 2007; 13(9-10): 495-508.
105. Felmet KA, Hall MW, Clark RS, Jaffe R, Carcillo JA. Prolonged lymphopenia, lymphoid depletion and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005; 174(6): 3765-3772.
106. Ronco C, Tetta C, Mariano F, et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: The peak concentration hypothesis. Artif. Organs 2003; 27: 792-801.
107. Osuchowski MF, Welch K, Siddiqui J, Remick DG. Circulating cytokine/ inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006; 177: 1967-1974.
108. Ashare A, Powers LS, Butler NS, Doerschug KC, Monick MM, Hunninghake GW. Anti-inflammatory response is associated with mortality and severity of infection in sepsis. Am J Physiol Lung Cell Mol Physiol 2005; 288: L633-L640.
109. Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: Restoration by IFN-gamma treatment. Nat Med 1997; 3(6): 678-681.
110. Volk HD, Reinke P, Krausch D, et al. Monocyte deactivation - rationale for a new therapeutic strategy in sepsis. Intensive Care Med 1996; 22(Suppl 4): S474-S481.
111. Kox WJ, Bone RC, Krausch D, et al. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: Proof of principle. Arch Intern Med 1997; 157: 389-393.
112. Bundschuh DS, Barsig J, Hartung T, et al. Granulocyte-macrophage colony-stimulating factor and IFN-gamma restore the systemic TNF-alpha response to endotoxin in lipopolysaccharide-desensitized mice. J Immunol 1997; 158: 2862-2871.
113. Pugin J. Immunostimulation is a rational therapeutic strategy in sepsis. Novartis Found Symp 2007; 280: 21-36: 160-164.
114. Nelson LA. Use of granulocyte-macrophage colony-stimulating factor to reverse anergy in otherwise immunologically healthy children. Ann Allergy Asthma Immunol 2007; 98: 373-382.
115. Spight D, Trapnell B, Zhao B, Berclaz P, Shanley TP. Granulocytemacrophage-colony-stimulating factor-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice. Shock 2008; 30: 434-442.
116. Flohe SB, Agrawal H, Flohe S, Rani M, Bangen JM, Schade FU. Diversity of interferon gamma and granulocyte-macrophage colony-stimulating factor in restoring immune dysfunction of dendritic cells and macrophages during polymicrobial sepsis. Mol Med 2008; 14: 247-256.
117. Wheeler DS, Wong HR. Genetic approach to pediatric septic shock. Personalized Med 2008; 5: 249-263.
118. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune dysfunctions in the septic patient: A new skin for the old ceremony. Mol Med 2008; 14: 64-78.
119. Marriott I, Huet-Hudson YM. Sexual dimorphism in innate immune responses to infectious organisms. Immunol Res 2006; 34: 177-192.
120. Choudhry MA, Bland KI, Chaudry IH. Trauma and immune response - effect of gender differences. Injury 2007; 38: 1382-1391.
121. Carcillo JA. Reducing the global burden of sepsis in infants and children: A clinical practice research agenda. Pediatr Crit Care Med 2005; 6: S157-S164.
122. Cave MC, Hurt RT, Frazier TH, et al. Obesity, inflammation, and the potential application of pharmaconutrition. Nutr Clin Pract 2008; 23: 16-34.
123. Nguyen TH, Nguyen TL, Lei HY, et al. Association between sex, nutritional status, severity of dengue hemorrhagic fever and immune status in infants with dengue hemorrhagic fever. Am J Trop Med Hyg 2005; 72: 370-374.
124. Sakr Y, Madl C, Filipescu D, et al. Obesity is associated with increased morbidity but not mortality in critically ill patients. Intensive Care Med 2008; 34: 1999-2009.
125. Cooke GS, Hill AV. Genetics of susceptibility to human infectious disease. Nat Rev Genet 2001; 2: 967-977.
126. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318(12): 727-732.
127. Arcaroli J, Fessler MB, Abraham E. Genetic polymorphisms in sepsis. Shock 2005; 24: 300-312.
128. Carlet J, Cohen J, Calandra T, Opal SM, Masur H. Sepsis: Time to reconsider the concept. Crit Care Med 2008; 36: 964-966.
129. Marshall JC. Such stuff as dreams are made on: Mediator-directed therapy in sepsis. Nat Rev Drug Discov 2003; 2: 391-405.
130. Sweeney DA, Danner RL, Eichacker PQ, Natanson C. Once is not enough: Clinical trials in sepsis. Intensive Care Med 2008; 34: 1955-1960.
131. Cobb JP, Mindrinos MN, Miller-Graziano C, et al. Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci USA 2005; 102(13): 4801-4806.
132. Wong HR. Pediatric septic shock treatment: new clues from genomic profiling. Pharmacogenomics 2007; 8(10): 1287-1290.
133. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: Retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med 2002; 166: 1197-1205.
134. Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, doubleblind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324(7): 429-436.
135. Abraham E, Glauser MP, Butler T, et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277(19): 1531-1538.
136. Fisher CJ Jr, Dhainaut JF, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271(23): 1836-1843.
137. Wong HR, Cvijanovich N, Wheeler DS, et al. Interleukin-8 as a stratification tool for interventional trials involving pediatric septic shock. Am J Respir Crit Care Med 2008; 178: 276-282.
138. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10: 399-415.
139. Akira S, Takeda K. Toll-like receptor signaling. Nat Rev Immunol 2004; 4: 499-511.
140. Franchi L, McDonald C, Kanneganti T-D, Amer.A, Nunez G. Nucleotide-binding oligomerization domain-like receptors: Intracellular pattern recognition molecules for pathogen detection and host defense. J Immunol 2006; 177: 3507-3513.
141. Zhang X, Mosser DM. Macrophage activation by endogenous danger signals. J Pathol 2008; 214: 161-178.
142. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521.
143. El Mezayen R, El Gazzar M, Seeds MC, McCall CE, Dreskin SC, Nicolls MR. Endogenous signals released from necrotic cells augment inflammatory responses to bacterial endotoxin. Immunol Lett 2007; 111: 36-44.
144. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-787.
145. Modlin RL, Brightbill HD, Godowski PJ. The toll of innate immunity on microbial pathogens. N Engl J Med 1999; 340(23): 1834-1835.
146. Underhill DM. Toll-like receptors and microbes take aim at each other. Curr Opin Immunol 2004; 16(4): 483-487.
147. Kopp EB, Medzhitov R. The Toll-like receptor family and control of innate immunity. Curr Opin Immunol 1999; 11: 13-18.
148. Gordon S. Pattern recognition receptors: Doubling up for the innate immune response. Cell 2002; 111: 927-930.
149. Akira S, Takeda K. Toll-like receptor signalling. Nat Immunol 2004; 4: 499-511.
150. Jefferies C, O'Neill LAJ. Signal transduction pathway activated by Toll-like receptors. Mod Asp Immunobiol 2002; 2: 169-175.
151. O'Neill LO. The Toll/interleukin-1 receptor domain: A molecular switch for inflammation and host defence. Biochem Soc Trans 2000; 28: 557-563.
152. Lakhani SA, Bogue CW. Toll-like receptor signaling in sepsis. Curr Opin Pediatr 2003; 15: 278-282.
153. Dauphinee SM, Karsan A. Lipopolysaccharide signaling in endothelial cells. Lab Invest 2006; 86: 9-22.
154. Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine 2008; 42: 145-151.
155. Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in TLR4 gene. Science 1998; 282: 2085-2088.
156. Qureshi ST, Lariviere L, Levegue G, et al. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (TLR4). J Exp Med1999; 189: 615-625.
157. Zingarelli B. Nuclear factor-kappaB. Crit Care Med 2005; 33: S414-S416.
158. Ghosh S, May MJ, Koop EB. NF-kappaB and Rel proteins: Evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-260.
159. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell 2008; 132: 344-362.
160. Hayden MS, West AP, Ghosh S. SnapShot: NF-kappaB signaling pathways. Cell 2006; 127: 1286-1287.
161. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002; 109: S81-S96.
162. Mesotten D, Vanhorebeek I, Van den Berghe G. The altered adrenal axis and treatment with glucocorticoids during critical illness. Nat Clin Pract Endocrinol Metab 2008; 4: 496-505.
163. VASSCS Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659-665.
164. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-658.
165. Lefering R, Neugebauer EA. Steroid controversy in sepsis and septic shock: A meta-analysis. Crit Care Med 1995; 23: 1294-303.
166. Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: A critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-1439.
167. Zimmerman JJ. A history of adjunctive glucocorticoid treatment for pediatric sepsis: Moving beyond steroid pulp fiction toward evidence-based medicine. Pediatr Crit Care Med 2007; 8: 530-539.
168. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-650.
169. Briegel J, Forst H, Haller M, et al. Stress dose of hydrocortisone reverse hyperdynamic septic shock: A prospective, randomized, double-blind, single-center study. Crit Care Med 1999; 27: 723-732.
170. O'Reilly SM, Moynagh PN. Regulation of Toll-like receptor 4 signaling by A20 zinc finger protein. Biochem Biophys Res Commun 2003; 303: 586-593.
171. Wullaert A, Verstrepen L, Van Huffel C, et al. LIND/ABIN-3 is a novel lipopolysaccharide-inducible inhibitor of NF-kappaB activation. J Biol Chem 2007; 282: 81-90.
172. Gilchrist M, Thorsson V, Li B, et al. Systems biology approaches identify ATF3 as a negative regulator of Toll-like receptor 4. Nature 2006; 441: 173-178.
173. Burns K, Janssens S, Brissoni B, Olivos N, Beyaert R, Tschopp J. Inhibition of interleukin 1 receptor/Toll-like receptor signaling through the alternatively spliced, short form of MyD88 is due to its failure to recruit IRAK-4. J Exp Med 2003; 197: 263-268.
174. Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol 2006; 7: 139-147.
175. Iwami KI, Matsuguchi T, Masuda A, Kikuchi T, Musikachareoen T, Yoshikai Y. Cutting edge: Naturally occurring soluble form of mouse Toll-like receptor 4 inhibits lipopolysaccharide signaling. J Immunol 2000; 165: 6682-6686.
176. Sweet MJ, Leung BP, Kang D, et al. A novel pathway regulating lipopolysaccharide-induced shock by ST2/T1 via inhibition of Tolllike receptor 4 expression. J Immunol 2001; 166: 6633-6639.
177. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science1990; 249: 1431-1433.
178. Divanovic S, Trompette A, Petiniot LK, et al. Regulation of TLR4 signaling and the host interface with pathogens and danger: The role of RP105. J Immunol 2007; 82: 265-271.
179. Wald D, Qin J, Zhao Z, et al. SIGIRR, a negative regulator of Tolllike receptor-interleukin-1 receptor signaling. Nat Immunol 2003; 4: 920-927.
180. Qin J, Qian Y, Grace C, Li X. SIGIRR inhibits interleukin-1 receptor-and toll-like receptor 4-mediated signaling through different mechanisms. J Biol Chem 2005; 280: 25233-25241.
181. Diehl GE, Yue HY, Hsieh K, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity 2004; 21: 877-889.
182. Cooper JT, Stroka DM, Brostjan C, Palmetschofer A, Bach FH, Ferran C. A20 blocks endothelial cell activation through a NFkappaB-dependent mechanism. J Biol Chem 1996; 271: 18068-18073.
183. Whitmore MM, Iparraguirre A, Kubelka L, Weninger W, Hai T, Williams BR. Negative regulation of TLR-signaling pathways by activating transcription factor-3. J Immunol 2007; 179: 3622-3630.
184. Fan H, Luttrell LM, Tempel GE, Senn JJ, Halushka PV, Cook JA. Beta-arrestins 1 and 2 differentially regulate LPS-induced signaling and proinflammatory gene expression. Mol Immunol 2007; 44: 3092-3099.
185. Shinohara H, Inoue A, Toyama-Sorimachi N, et al. Dok-1 and Dok-2 are negative regulators of lipopolysaccharide-induced signaling. J Exp Med 2005; 201: 333-339.
186. Kobayashi K, Hernandez LD, Galan JE, Janeway CAJ, Medzhitov R, Flavell RA. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 2002; 110: 191-202.
187. Williams KL, Lich JD, Duncan JA, et al. The CATERPILLAR protein monarch-1 is an antagonist of toll-like receptor, tumor necrosis factor alpha, and Mycobacterium tuberculosis-induced proinflammatory signals. J Biol Chem 2005; 280: 39914-39924.
188. Cole AM, Waring AJ. The role of defensins in lung biology and therapy. Am J Respir Med 2002; 1: 249-259.
189. Beisswenger C, Bals R. Antimicrobial peptides in lung inflammation. Chem Immunol Allergy 2005; 86: 55-71.
190. Hiemstra PS. The role of epithelial beta-defensins and cathelicidins in host defense of the lung. Exp Lung Res 2007; 33: 537-542.
191. Giacometti A, Cirioni O, Ghiselli R, et al. Amphibian peptides prevent endotoxemia and bacterial translocation in bile duct-ligated rats. Crit Care Med 2006; 34: 2415-2420.
192. Mangoni ML, Marcellini HG, Simmaco M. Biological characterization and modes of action of temporins and bombinins H, multiple forms of short and mildly cationic anti-microbial peptides from amphibian skin. J Pept Sci 2007; 13: 603-613.
193. Cirioni O, Ghiselli R, Orlando F, et al. Efficacy of the amphibian peptide distinctin in a neutropenic mouse model of staphylococal sepsis. Crit Care Med 2008; 36: 2629-2633.
194. Andra J, Gutsmann T, Garidel P, Brandenburg K. Mechanisms of endotoxin neutralization by synthetic cationic compounds. J Endotoxin Res 2006; 12: 261-277.
195. Bosshart H, Heinzelmann M. Targeting bacterial endotoxin: Two sides of a coin. Ann N Y Acad Sci 2007; 1096: 1-17.
196. Arana Mde J, Vallespi MG, Chinea G, et al. Inhibition of LPSresponses by synthetic peptides derived from LBP associates with the ability of the peptides to block LBP-LPS interactions. J Endotoxin Res 2003; 9: 281-291.
197. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529-6532.
198. Reinhart K, Gluck T, Ligtenberg J, et al. CD14 receptor occupancy in severe sepsis: Results of a phase I clinical trial with a recombinant chimeric CD14 monoclonal antibody (IC14). Crit Care Med 2004; 32: 1100-1108.
199. Leturcq, D.J., Moriarty, A.M., Ulevitch, R.J., Tobias, P.S., Mathison, J.C.: US20087326569 (2008).
200. Wendel M, Paul R, Heller AR. Lipoproteins in inflammation and sepsis. II. Clinical aspects. Intensive Care Med 2007; 33: 25-35.
201. Wu A, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: Metabolism, actions, and therapeutic applications. Shock 2004; 21: 210-221.
202. Wheeler DS, Wong HR. Heat shock response and acute lung injury. Free Radic Biol Med 2007; 42: 1-14.
203. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A. HMGB1: Endogenous danger signaling. Mol Med 2008; 14: 476-484.
204. Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999; 285: 248-251.
205. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101: 296-301.
206. Matthews RC, Rigg G, Hodgetts S, et al. Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrob Agents Chemother 2003; 47: 2208-2216.
207. Pachl J, Svoboda P, Jacobs F, et al. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 2006; 42: 1404-1413.
208. Sutherland A, Ellis D. Treatment of a critically ill child with disseminated Candida glabrata with a recombinant human antibody specific for fungal heat shock protein 90 and liposomal amphotericin B, caspofungin, and voriconazole. Pediatr Crit Care Med 2008; 9: e23-e25.
209. Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxyygeldanamycin in pediatric patients with recurrent or refractory solid tumors: A pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007; 13: 1783-1788.
210. Weigel BJ, Blaney SM, Reid JM, et al. A phase I study of 17-allylaminogeldanamycin in relasped/refractory pediatric patients with solid tumors: A Children's Oncology Group Study. Clin Cancer Res 2007; 13: 1789-1793.
211. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs 2002; 7(2): 277-288.
212. Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: A double-blind randomised trial. Lancet 2006; 368: 855-863.
213. Raz I, Avron A, Tamir M, et al. Treatment of new-onset type 1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: Extension of a randomized, doubleblind, phase II trial. Diabetes Metab Res Rev 2007; 23: 292-298.
214. Lynn M, Rossignol DP, Wheeler JL, et al. Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia. J Infect Dis 2003; 187: 631-639.
215. Rossignol DP, Lynn M. Anatagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue. J Endotoxin Res 2002; 8: 483-488.
216. Hawkins LD, Christ WJ, Rossignol DP. Inhibition of endotoxin response by synthetic TLR4 antagonists. Curr Top Med Chem 2004; 4: 1147-1171.
217. Bennet-Guerrero E, Grocott HP, Levy JH, et al. A phase II, doubleblind, placebo-controlled, ascending-dose study of eritoran (E5564), a lipid antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth Analg 2007; 104: 378-383.
218. Zingarelli B, Sheehan M, Wong HR. Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 2003; 31: S105-S111.
219. Abraham E. Nuclear factor-kappaB and its role in sepsis-associated organ failure. J Infect Dis 2003; 187: S364-S369.
220. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor kappa B: An emerging theme in anti-inflammatory therapies. Mol Interv 2002; 2: 22-35.
221. Jagetia GC, Aggarwal BB. "Spicing up" of the immune system by curcumin. J Clin Immunol 2007; 27: 19-35.
222. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: From ancient medicine to current clinical trials. Cell Mol Life Sci 2008; 65: 1631-1652.
223. Sheehan M, Wong HR, Hake PW, Malhotra V, O'Connor M, Zingarelli B. Parthenolide, an inhibitor of the nuclear factorkappaB pathway, ameliorates cardiovascular derangement and outcome in endotoxic shock in rodents. Mol Pharmacol 2002; 61: 953-963.
224. Sheehan M, Wong HR, Hake PW, Zingarelli B. Parthenolide improves systemic hemodynamics and decreases tissue leukosequestration in rats with polymicrobial sepsis. Crit Care Med 2003; 31: 2263-2270.
225. Sheehan M, Wong HR, Hake PW, Zingarelli B. Protective effects of isohelenin, an inhibitor of nuclear factor kappaB, in endotoxic shock in rats. J Endotoxin Res 2002; 8: 99-107.
226. Wheeler DS, Wheeler WJ. The medicinal chemistry of tea. Drug Dev Res 2004; 61: 45-65.
227. Yang F, de Villiers WJ, McClain CJ, Varilek GW. Green tea polyphenols block endotoxin-induced tumor necrosis factor-production and lethality in a murine model. J Nutr 1998; 128: 2334-2340.
228. Chen PC, Wheeler DS, Malhotra V, Odoms K, Denenberg AG, Wong HR. A green tea-derived polyphenol, epigallocatechin-3-gallate, inhibits IkappaB kinase activation and IL-8 gene expression in respiratory epithelium. Inflammation 2002; 26: 233-241.
229. Wheeler DS, Catravas JD, Odoms K, Denenberg A, Malhotra V, Wong HR. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1-beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr 2004; 134: 1039-1044.
230. Aneja R, Odoms K, Denenberg AG, Wong HR. Theaflavin, a black tea extract, is a novel anti-inflammatory compound. Crit Care Med 2004; 32: 2097-2103.
231. Uwe S. Anti-inflammatory interventions and NF-kappaB signaling: Potential applications and risks. Biochem Pharmacol 2008; 75: 1567-1579.
232. Alvira CM, Abate A, Yang G, Dennery PA, Rabinovitch M. Nuclear factor-kappaB activation in neonatal mouse lung protects against lipopolysaccharide-induced inflammation. Am J Respir Crit Care Med 2007; 175: 805-815.
233. Gadjeva M, Tomczak MF, Zhang M, et al. A role for NF-kappaB subunits p50 and p65 in the inhibition of lipopolysaccharide-induced shock. J Immunol 2004; 173: 5786-5793.
234. Li X, Cui X, Li Y, Fitz Y, Hsu L, Eichacker PQ. Parthenolide has limited effects on nuclear factor-kappaB increases and worsens survival in lipopolysacchardie-challenged C57BL/6J mice. Cytokine 2006; 33: 299-308.
235. Su J, Li X, Cui X, et al. Ethyl pyruvate decreased early nuclear factor-kappB levels but worsened survival in lipopolysaccharide-challenged mice. Crit Care Med 2008; 36: 1059-1067.